Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Etienne Chatelut

Showing results (1-10 of 161) with videos related to

Pageof 17
Sort By:
Bulletin Du Cancer|October 26, 2011
[Pharmacology of platinum compounds: differences between the three molecules and factors of interpatient variability]Etienne Chatelut
Bulletin Du Cancer|October 26, 2011
[Pharmacokinetics and impaired organic functions]Etienne Chatelut
Fundamental & Clinical Pharmacology|December 4, 2008
Population approaches in paediatricsEtienne Chatelut
Bulletin Du Cancer|November 14, 2008
[Anticancer drug dose individualisation: from body surface area to physiology]Aurélie Pétain, Etienne Chatelut
The Oncologist|October 12, 2020
Correlation Between Bevacizumab Exposure and Survival Does Not Necessarily Imply CausalityFélicien Le Louedec, Etienne Chatelut
Anticancer Research|January 10, 2014
Standardization of chemotherapy and individual dosing of platinum compoundsFlorent Puisset, Antonin Schmitt, Etienne Chatelut
Clinical Pharmacology and Therapeutics|December 2, 2017
Intraindividual Pharmacokinetic Variability: Focus on Small-Molecule Kinase InhibitorsEtienne Chatelut, René Bruno, Mark J Ratain
Investigational New Drugs|August 2, 2003
Toxicity patterns of cytotoxic drugsEtienne Chatelut, Jean-Pierre Delord, Pierre Canal
Clinical Pharmacokinetics|November 9, 2019
Setting the Dose of Checkpoint Inhibitors: The Role of Clinical PharmacologyEtienne Chatelut, Félicien Le Louedec, Gérard Milano
Clinical Pharmacokinetics|July 11, 2016
Population Pharmacokinetics of Tracers: A New Tool for Medical Imaging?Peggy Gandia, Cyril Jaudet, Etienne Chatelut, et al.
Pageof 17

Showing results (1-10 of 161) with videos related to

Sort By:
Pageof 17
Bulletin Du Cancer|October 26, 2011
[Pharmacology of platinum compounds: differences between the three molecules and factors of interpatient variability]Etienne Chatelut
Bulletin Du Cancer|October 26, 2011
[Pharmacokinetics and impaired organic functions]Etienne Chatelut
Fundamental & Clinical Pharmacology|December 4, 2008
Population approaches in paediatricsEtienne Chatelut
Bulletin Du Cancer|November 14, 2008
[Anticancer drug dose individualisation: from body surface area to physiology]Aurélie Pétain, Etienne Chatelut
The Oncologist|October 12, 2020
Correlation Between Bevacizumab Exposure and Survival Does Not Necessarily Imply CausalityFélicien Le Louedec, Etienne Chatelut
Anticancer Research|January 10, 2014
Standardization of chemotherapy and individual dosing of platinum compoundsFlorent Puisset, Antonin Schmitt, Etienne Chatelut
Clinical Pharmacology and Therapeutics|December 2, 2017
Intraindividual Pharmacokinetic Variability: Focus on Small-Molecule Kinase InhibitorsEtienne Chatelut, René Bruno, Mark J Ratain
Investigational New Drugs|August 2, 2003
Toxicity patterns of cytotoxic drugsEtienne Chatelut, Jean-Pierre Delord, Pierre Canal
Clinical Pharmacokinetics|November 9, 2019
Setting the Dose of Checkpoint Inhibitors: The Role of Clinical PharmacologyEtienne Chatelut, Félicien Le Louedec, Gérard Milano
Clinical Pharmacokinetics|July 11, 2016
Population Pharmacokinetics of Tracers: A New Tool for Medical Imaging?Peggy Gandia, Cyril Jaudet, Etienne Chatelut, et al.
Pageof 17